Figures cited from named public press (CereVasc IR and matching trade items retrieved 1 September 2026) and the published bioaccess® Argentina country page. Press mention_n is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current ANMAT, ethics, provincial, and FDA rules with qualified advisers. We name only the facility, PI, and sponsor those sources support. We do not invent a CRO the wires did not name. We do not claim Clínica la Sagrada Familia, ENERI, or CereVasc as a bioaccess® client.
If you searched Clínica la Sagrada Familia first-in-human, ENERI Buenos Aires CRO, Pedro Lylyk eShunt, or “go direct Sagrada Familia Argentina,” you followed a hospital name that is genuinely in the public file. Clínica la Sagrada Familia (ENERI) in Buenos Aires is a real neuroendovascular site. It is not a first-in-human medical-device CRO, and it is not the operator of the ANMAT file.
bioaccess®’s position is simple and it is not adversarial: the clinic is the site. The First-in-Human CRO still owns ANMAT, independent ethics, provincial oversight, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if Buenos Aires is not the only fit. Sponsors who skip the CRO and email the clinic still have to rebuild that stack. A press release that names the building does not become a CRO.
This page is the intercept for the Buenos Aires press cluster. It does not clone Hospital Italiano Asunción FIH (CMS 95517 — Paraguay, DINAVISA, a different building). It is also not Hospital Italiano de Buenos Aires (HIBA; a different NCT campus string). Linking is correct. Merging Asunción, HIBA, and Sagrada Familia is not.
Why the clinic name wins the search — and why that is not a CRO
Device press writes the implant, the city, the hospital, and the surgeon. It rarely writes the CRO. On the 1 September 2026 LATAM device FIH/EFS press sweep, Clínica la Sagrada Familia (ENERI), Buenos Aires, Argentina, is rank 3, mention_n=8. Example URLs the ranking actually used:
- CereVasc IR, 10 February 2021 — first patient in a study of the investigational eShunt™ System for communicating hydrocephalus. Site: Clinica Sagrada Familia. PI named: Dr. Pedro Lylyk. Trial name: ETCHES I. No CRO.
- CereVasc IR, 7 December 2021 and the matching Endovascular Today item — FIH case report; Clinica la Sagrada Familia; Lylyk named. No CRO.
- PR Newswire, 30 July 2025 — 100th eShunt patient (pilot plus STRIDE), treated by Dr. Pedro Lylyk at Clinica la Sagrada Familia. The release names him CEO of ENERI and Clinica la Sagrada Familia and co-lead investigator of STRIDE. No CRO.
- CereVasc IR, 21 January 2026 plus Endovascular Today and NeuroNews rewrites — ETCHES enrollment complete; Clinica la Sagrada Familia; Lylyk named. No CRO.
That is useful public information about a press-named Buenos Aires FIH site. It is how a founder googles “Lylyk eShunt” or “Sagrada Familia first-in-human” and lands on a clinic without landing on ANMAT, importer of record, ISO 14155, or 21 CFR 812.28. We cite those URLs as facility evidence. We will not invent a CRO. We will not claim bioaccess® ran ETCHES I, STRIDE, or any CereVasc program. No live bioaccess® case-study page names this clinic as a client site.
The site is the site. The CRO is the operator.
A Buenos Aires neuroendovascular clinic can provide rooms, imaging, coordinators, and an investigator the sponsor already put in the wire. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.
What the clinic can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing neuroendovascular service.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the cases they will physically run.
What the clinic is not built to own for an investigational device:
- ANMAT. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. The published Argentina hub puts a 90-business-day statutory review target on submitted clinical-trial documents; the clock pauses for RFIs, and FIH/EFS device studies often exceed that target. A hallway conversation in Recoleta is not that dossier.
- Independent ethics plus provincial oversight (Buenos Aires). Those packages sit alongside the federal file. Sequential filing adds time.
- Investigational import into Argentina is a separate permit from trial authorization and from later market registration. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. We will not invent a Sagrada Familia-only premium here.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The clinic may run the case. The CRO runs the quality system the FDA will later ask about.
- The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after GCP / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
- Multi-country optionality. If Buenos Aires enrollment or the indication later needs Colombia, Paraguay, or Panama, a single-clinic MSA will not stretch.
Going direct to Clínica la Sagrada Familia is how you confirm a room. It is not how you open an investigational file.
Site versus CRO
| Workstream | What Sagrada Familia / ENERI (site) typically owns | What the CRO still owns |
|---|---|---|
| Procedure | Rooms, imaging, neuroendovascular service, local staff | Protocol fit, training, device accountability |
| Ethics | Institutional / independent committee calendar and local rules | Packet, ICF, IB alignment, deficiency cycle |
| National authority | Not the permit holder by appearing in a CereVasc IR | ANMAT clinical-trial authorization (90-business-day statutory target; clock pauses apply) |
| Provincial | Local Buenos Aires research rules if they apply to the host | Provincial filings in parallel with the federal file |
| Import | Receiving and storage if contracted | Importer of record |
| Quality | Clinic quality and the case | ISO 14155 monitoring, EDC, SAE, TMF |
| FDA conversation | Source documents from cases they run | 21 CFR 812.28 narrative — eligibility, not clearance |
| Country optionality | One Buenos Aires clinic | Colombia (INVIMA) and the rest of the bioaccess® platform |
How ANMAT actually works (the short version)
Use clinical-trials-argentina for the full pathway. Facts a sponsor searching this clinic needs on one screen, already published there and not re-averaged here:
- ANMAT is the national authority for medicines, medical devices, and clinical research.
- Statutory review target: 90 business days. The clock pauses for agency queries. FIH/EFS device studies commonly exceed the target. Treat it as a planning framework, not a guaranteed start.
- Independent ethics committee approval under ISO 14155, plus provincial oversight (e.g., Buenos Aires).
- Headline ~30% lower per-patient cost versus typical US/EU programs is experience since 2010, not a formal study. ANMAT device registration is a second, separate file. This site does not publish ANMAT as PAHO/WHO Level 4.
- Under 21 CFR 812.28, foreign clinical data from Argentina is eligible for FDA submission and review when studies are conducted under ISO 14155 with proper ANMAT authorization and ethics approval. Eligibility is not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Ask for a protocol-specific calendar. A clinic email is not an ANMAT approval. bioaccess® manages the file. That is CRO work, not site work.
All bioaccess® Argentina device protocols are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval.
Do not smear the clinic — and do not merge Buenos Aires with Asunción
Clínica la Sagrada Familia and ENERI are a serious neuroendovascular resource. Eight independent press URLs naming the building is a signal of public visibility, not a punchline. This page is not a critique of that work. Visibility in CereVasc copy is still not a device-CRO quality system. Use the site when the protocol fits. Hire the operator.
Do not merge this clinic into Hospital Italiano de Buenos Aires. Do not merge it into Hospital Italiano / Sanatorio Italiano, Asunción. Different countries. Different regulators (ANMAT vs DINAVISA). Different investigators in the public file.
What the CRO still does after you have a Sagrada Familia slide
- Regulatory-fit, not tourism. Argentina is a sourced device geography. One Buenos Aires clinic is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the ANMAT / ethics / provincial packet.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate Sagrada Familia / ENERI only if it fits the protocol.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a press-named clinic.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Can I contract Clínica la Sagrada Familia or ENERI directly for a device FIH?
You can try. The clinic can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by appearing in eight CereVasc URLs, become your ANMAT applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.
Did bioaccess® run the eShunt / ETCHES I / STRIDE work named here?
No public bioaccess® case-study page names this clinic. We will not invent that claim. This page intercepts the search; it does not claim the studies. mention_n=8 is a press-URL count, not bioaccess® enrollment.
Is this the same hospital as Hospital Italiano de Buenos Aires or Hospital Italiano Asunción?
No. HIBA is a different Buenos Aires campus (NCT intercept, not this press cluster). Hospital Italiano Asunción is Paraguay. Do not merge them.
If I already have Dr. Lylyk, what does the CRO still do?
Regulatory-fit (Argentina vs Colombia vs a multi-country design); the ANMAT / ethics / provincial packet; insurance; import; contracts and activation; ISO 14155 and the 812.28 narrative; optionality if one Buenos Aires room is not enough. A named PI is the site. He is not the CRO.
Next step
If the search that brought you here was Clínica la Sagrada Familia, ENERI, or Pedro Lylyk, start as the operator: contact bioaccess® or book from First-in-Human CRO. Country: clinical trials in Argentina. Distinct Paraguay hospital: Hospital Italiano Asunción.
Julio G. Martinez-Clark, CEO · bioaccess®